Heme oxygenase-1 induction may explain the antioxidant profile of aspirin

被引:137
作者
Grosser, N
Abate, A
Oberle, S
Vreman, HJ
Dennery, PA
Becker, JC
Pohle, T
Seidman, DS
Schröder, H
机构
[1] Univ Halle Wittenberg, Sch Pharm, Dept Pharmacol & Toxicol, D-06099 Halle Saale, Germany
[2] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA
[3] Univ Munster, Dept Med B, D-48129 Munster, Germany
[4] Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Obstet & Gynecol, IL-69978 Tel Aviv, Israel
关键词
antioxidant; bilirubin; carbon monoxide; cell injury; cytoprotection; endothelial cells; gene expression; heme oxygenase; nitric oxide; aspirin;
D O I
10.1016/S0006-291X(03)01504-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aspirin is known to exert antioxidant effects by as yet unidentified mechanisms. In cultured endothelial cells derived from human umbilical vein, aspirin (30-300 muM) increased heme oxygenase-1 (HO-1) protein levels in a concentration-dependent fashion up to fivefold over basal levels. HO-1 induction was accompanied by a marked increase in catalytic activity of the enzyme as reflected by enhanced formation of both carbon monoxide and bilirubin. Pretreatment with aspirin or bilirubin at low micromolar concentrations protected endothelial cells from hydrogen peroxide-mediated toxicity. HO-1 induction and endothelial protection by aspirin were not mimicked by indomethacin, another inhibitor of cyclooxygenase. The nitric oxide (NO) synthase blocker L-NAME prevented aspirin-dependent HO-1 induction. These findings demonstrate that aspirin targets HO-1, presumably via NO-dependent pathways. Induction of HO-1 expression and activity may be a novel mechanism by which aspirin prevents cellular injury under inflammatory conditions and in cardiovascular disease. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:956 / 960
页数:5
相关论文
共 38 条
  • [1] Appleton SD, 1999, DRUG METAB DISPOS, V27, P1214
  • [2] THE IRON-BINDING AND HYDROXYL RADICAL SCAVENGING ACTION OF ANTI-INFLAMMATORY DRUGS
    ARUOMA, OI
    HALLIWELL, B
    [J]. XENOBIOTICA, 1988, 18 (04) : 459 - 470
  • [3] Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
  • [4] SUPPRESSION OF THROMBOXANE-A2 BUT NOT OF SYSTEMIC PROSTACYCLIN BY CONTROLLED-RELEASE ASPIRIN
    CLARKE, RJ
    MAYO, G
    PRICE, P
    FITZGERALD, GA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (16) : 1137 - 1141
  • [5] Carbon monoxide in vasoregulation - The promise and the challenge
    Coceani, F
    [J]. CIRCULATION RESEARCH, 2000, 86 (12) : 1184 - 1186
  • [6] Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice
    Cyrus, T
    Sung, S
    Zhao, L
    Funk, CD
    Tang, S
    Praticò, D
    [J]. CIRCULATION, 2002, 106 (10) : 1282 - 1287
  • [7] COMPARISON OF INVITRO-CELL CYTO-TOXIC ASSAYS FOR TUMOR NECROSIS FACTOR
    FLICK, DA
    GIFFORD, GE
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1984, 68 (1-2) : 167 - 175
  • [8] ASPIRIN AS A THERAPEUTIC AGENT IN CARDIOVASCULAR-DISEASE
    FUSTER, V
    DYKEN, ML
    VOKONAS, PS
    HENNEKENS, C
    [J]. CIRCULATION, 1993, 87 (02) : 659 - 675
  • [9] GROSSER N, 2003, UNPUB ARTERIOSCLER T
  • [10] Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease
    Hopkins, PN
    Wu, LL
    Hunt, SC
    James, BC
    Vincent, GM
    Williams, RR
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (02) : 250 - 255